NEW YORK, Oct. 2 – Drug discovery company Pharmacopeia of Princeton, NJ, said Tuesday it has agreed to collaborate with German pharmaceutical company Boehringer Ingelheim to identify lead compounds for an undisclosed target.
Under the terms of the deal, Pharmacopeia will help Boehringer Ingelheim to develop assays and will provide the company with compound samples. In addition, Pharmacopeia will also provide high-throughput screening technology services.
In exchange, Pharmacopeia said it would receive fees and additional milestone payments of an undisclosed amount.
"Pharmacopeia's compound pool complements Boehringer Ingelheim's sample collection," Dieter Hinzen, head of research and development at Boehringer Ingelheim Pharma, a subsidiary of Boehringer Ingelheim, said in a statement.
"Boehringer Ingelheim expects to identify attractive lead compounds for one of our innovative targets from Pharmacopeia's large collection of small molecules," Hinzen said.
Pharmacopeia's drug discovery unit integrates small molecule combinatorial and medicinal chemistry, high-throughput screening, in-vitro pharmacology, computational methods, and informatics to discover and optimize lead compounds.
In addition to drug discovery, Pharmacopeia also operates a software business, Accelrys. In July, the company said it was considering spinning Accelrys off from its drug discovery businesses.
Boehringer Ingelheim of Ingelheim, Germany is a leading pharmaceutical company.